Optical coherence tomography-based decision making in exudative age-related macular degeneration: comparison of time- vs spectral-domain devices.
OBJECTIVE
To determine whether optical coherence tomography (OCT) device-type influences clinical grading of OCT imaging in the context of exudative age-related macular degeneration (AMD).


METHODS
Ninety-six paired OCT scans from 49 patients with active exudative AMD were obtained on both the time-domain Stratus OCT system and the spectral-domain Cirrus OCT system at the same visit. Three independent graders judged each scan for the presence of intraretinal fluid (IRF) or subretinal fluid (SRF). The degree of grader consensus was evaluated and the ability of the systems to detect the presence of disease activity was analysed.


RESULTS
Cirrus OCT generated a higher degree of inter-grader consensus than Stratus OCT with higher intraclass correlation coefficients for all parameters analysed. A pair-wise comparison of Cirrus OCT with Stratus OCT systems revealed that Cirrus-based gradings more frequently reported the presence of SRF and IRF and detected overall neovascular activity at a higher rate (P<0.05) compared with Stratus-based gradings.


CONCLUSIONS
The choice of time-domain (Stratus) vs spectra-domain (Cirrus) OCT systems has a measurable impact on clinical decision making in exudative AMD. Spectral-domain OCT systems may be able to generate more consensus in clinical interpretation and, in particular cases, detect disease activity not detected by time-domain systems. Clinical trials using OCT-based clinical evaluations of exudative AMD may need to account for these inter-system differences in planning and analysis.
Cukras
C
C
Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Wang
Y D
YD
Meyerle
C B
CB
Forooghian
F
F
Chew
E Y
EY
Wong
W T
WT
D003657:Decision Making; D005122:Exudates and Transudates; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis*; D009389:Neovascularization, Pathologic / Q000473:pathology; D012160:Retina / Q000473:pathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence / Q000295:instrumentation / Q000379:methods*
Invest Ophthalmol Vis Sci. 2008 May;49(5):2046-52
18436839
Ophthalmology. 1996 Aug;103(8):1260-70
8764797
Ophthalmology. 2007 Oct;114(10):1868-75
17628683
Arch Ophthalmol. 2005 Oct;123(10):1330-7
16219723
Am J Ophthalmol. 2007 Apr;143(4):566-83
17386270
Ophthalmology. 2006 Nov;113(11):2002.e1-12
17027972
Am J Ophthalmol. 2007 Oct;144(4):627-37
17893015
Br J Ophthalmol. 2008 Mar;92(3):356-60
18303156
Ophthalmology. 2003 Feb;110(2):400-5
12578787
Arch Ophthalmol. 2001 Aug;119(8):1135-42
11483079
Ophthalmology. 2009 May;116(5):947-55
19232732
Am J Ophthalmol. 2007 Jul;144(1):37-44
17509508
Ophthalmology. 2009 May;116(5):964-70
19410954
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3378-85
19264895
Am J Ophthalmol. 2004 Jan;137(1):156-69
14700659
Arch Ophthalmol. 2008 Jan;126(1):45-50
18195217